Northern Trust’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$76.8M Buy
445,382
+6,221
+1% +$1.15M 0.01% 867
2025
Q4
$87.6M Sell
439,161
-37,303
-8% -$6.77M 0.01% 797
2025
Q3
$74.5M Sell
476,464
-721
-0.2% -$115K 0.01% 881
2025
Q2
$72.4M Sell
477,185
-15,285
-3% -$2.04M 0.01% 870
2025
Q1
$74.1M Buy
492,470
+252
+0.1% +$42.3K 0.01% 847
2024
Q4
$90.9M Buy
492,218
+58,398
+13% +$11.2M 0.01% 774
2024
Q3
$85.4M Sell
433,820
-24,077
-5% -$5M 0.01% 712
2024
Q2
$94.6M Sell
457,897
-1,354
-0.3% -$307K 0.02% 650
2024
Q1
$124M Sell
459,251
-21,135
-4% -$5.05M 0.02% 555
2023
Q4
$114M Sell
480,386
-17,081
-3% -$3.36M 0.02% 579
2023
Q3
$97.5M Buy
497,467
+24,249
+5% +$4.98M 0.02% 603
2023
Q2
$99.5M Sell
473,218
-17,809
-4% -$3.54M 0.02% 603
2023
Q1
$99.1M Sell
491,027
-5,272
-1% -$1.19M 0.02% 605
2022
Q4
$108M Buy
496,299
+1,724
+0.3% +$376K 0.02% 555
2022
Q3
$97.3M Sell
494,575
-5,484
-1% -$1.18M 0.02% 552
2022
Q2
$107M Sell
500,059
-5,786
-1% -$1.41M 0.02% 545
2022
Q1
$144M Sell
505,845
-11,644
-2% -$3.59M 0.03% 532
2021
Q4
$195M Sell
517,489
-9,860
-2% -$3.83M 0.03% 458
2021
Q3
$218M Buy
527,349
+14,387
+3% +$5.98M 0.04% 417
2021
Q2
$190M Buy
512,962
+75,720
+17% +$25.3M 0.03% 461
2021
Q1
$127M Buy
437,242
+40,500
+10% +$11.3M 0.02% 583
2020
Q4
$99.1M Sell
396,742
-9,318
-2% -$2.22M 0.02% 644
2020
Q3
$92M Sell
406,060
-18,041
-4% -$3.74M 0.02% 598
2020
Q2
$73.9M Buy
424,101
+12,444
+3% +$1.99M 0.02% 649
2020
Q1
$52M Buy
411,657
+18,226
+5% +$2.73M 0.01% 756
2019
Q4
$60.1M Buy
393,431
+8,372
+2% +$1.16M 0.01% 885
2019
Q3
$51M Sell
385,059
-1,937
-0.5% -$260K 0.01% 959
2019
Q2
$54.9M Buy
386,996
+3,504
+0.9% +$475K 0.01% 923
2019
Q1
$55.7M Buy
383,492
+10,570
+3% +$1.39M 0.01% 880
2018
Q4
$42.2M Buy
372,922
+3,193
+0.9% +$400K 0.01% 990
2018
Q3
$49.7M Sell
369,729
-10,669
-3% -$1.32M 0.01% 1032
2018
Q2
$42.7M Sell
380,398
-31,649
-8% -$3.42M 0.01% 1148
2018
Q1
$44M Sell
412,047
-11,600
-3% -$1.25M 0.01% 1083
2017
Q4
$46.4M Sell
423,647
-2,652
-0.6% -$289K 0.01% 1028
2017
Q3
$46M Sell
426,299
-10,561
-2% -$1.09M 0.01% 1023
2017
Q2
$44.2M Buy
436,860
+6,304
+1% +$580K 0.01% 1019
2017
Q1
$38.7M Buy
430,556
+10,133
+2% +$861K 0.01% 1120
2016
Q4
$32M Buy
420,423
+251
+0.1% +$19.1K 0.01% 1231
2016
Q3
$35M Buy
420,172
+9,496
+2% +$796K 0.01% 1114
2016
Q2
$33.9M Buy
410,676
+3,597
+0.9% +$296K 0.01% 1083
2016
Q1
$30.7M Buy
407,079
+13,574
+3% +$1M 0.01% 1147
2015
Q4
$31.6M Sell
393,505
-3,922
-1% -$283K 0.01% 1132
2015
Q3
$25.2M Buy
397,427
+6,339
+2% +$455K 0.01% 1322
2015
Q2
$27.5M Sell
391,088
-8,152
-2% -$603K 0.01% 1317
2015
Q1
$31.7M Sell
399,240
-4,288
-1% -$316K 0.01% 1219
2014
Q4
$25.7M Buy
403,528
+20,846
+5% +$1.31M 0.01% 1343
2014
Q3
$22.9M Sell
382,682
-22,336
-6% -$1.28M 0.01% 1396
2014
Q2
$21.7M Buy
405,018
+9,550
+2% +$524K 0.01% 1454
2014
Q1
$23.9M Buy
395,468
+1,939
+0.5% +$113K 0.01% 1432
2013
Q4
$20.9M Sell
393,529
-3,656
-0.9% -$184K 0.01% 1489
2013
Q3
$18.4M Sell
397,185
-11,860
-3% -$544K 0.01% 1520
2013
Q2
$16.8M Buy
+409,045
New +$17.5M 0.01% 1515

Other funds holding CRL

Northern Trust's CRL Position: Q1 2026 in Review

Northern Trust increased its Charles River Laboratories (CRL) stake by 1.4% in Q1 2026, buying an estimated $1.15M and bringing the position to 445,382 shares worth $76.8M. The position accounts for 0.01% of the portfolio, ranked #867.

Northern Trust first reported a position in CRL in Q2 2013 and has held it in 52 quarters since. The position peaked at $218M in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Northern Trust held 445,382 shares of Charles River Laboratories worth $76.8M as of Q1 2026.
  • Northern Trust bought 6,221 Charles River Laboratories shares in Q1 2026, an estimated $1.15M.
  • Charles River Laboratories made up 0.01% of Northern Trust's portfolio in Q1 2026, its #867 holding.
  • Northern Trust first reported a position in Charles River Laboratories in Q2 2013 and has held it in 52 quarters since.
  • Northern Trust's Charles River Laboratories position peaked at $218M in Q3 2021.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.